Alnylam Pharmaceuticals' Capital Expenditures rose 189.65% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year increase of 9.90%. This contributed to the annual value of $34.3 million for FY2024, which is 44.90% down from last year.
Per Alnylam Pharmaceuticals' latest filing, its Capital Expenditures stood at $12.1 million for Q3 2025, which was down 15.05% from $14.3 million recorded in Q2 2025.
Over the past 5 years, Alnylam Pharmaceuticals' Capital Expenditures peaked at $26.1 million during Q3 2021, and registered a low of $4.2 million during Q3 2024.
In the last 3 years, Alnylam Pharmaceuticals' Capital Expenditures had a median value of $13.0 million in 2024 and averaged $12.0 million.
Its Capital Expenditures has fluctuated over the past 5 years, first slumped by 75.47% in 2024, then spiked by 189.65% in 2025.
Alnylam Pharmaceuticals' Capital Expenditures (Quarterly) stood at $21.9 million in 2021, then declined by 1.15% to $21.6 million in 2022, then decreased by 29.24% to $15.3 million in 2023, then crashed by 40.60% to $9.1 million in 2024, then skyrocketed by 189.65% to $12.1 million in 2025.
Its Capital Expenditures was $12.1 million in Q3 2025, compared to $14.3 million in Q2 2025 and $9.0 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value